Pegcetacoplan combines a complement-targeting cyclic peptide with polyethylene glycol chains to modulate solubility and hydrodynamic radius. The PEGylated architecture decreases aggregation and can prolong circulation in model systems. Researchers examine its binding to complement components, conformational features, and complex formation. Applications include complement-pathway mechanism studies, ligand-protein interaction analysis, and bioconjugate-engineering work.
CAT No: R2736
CAS No:2019171-69-6
Synonyms/Alias:Pegcetacoplan; 2019171-69-6; TO3JYR3BOU; Syfovre; APL-2; APL 2; APL-2 peptide; APL2; O,O'-BIS((S2,S12-CYCLO(N-ACETYL-L-ISOLEUCYL-L-CYSTEINYL-L-VALYL-1-METHYL-L-TRYPTOPHYL-L-GLUTAMINYL-L-alpha-ASPARTYL-L-TRYPTOPHYLGLYCYL-L-ALANYL-L-HISTIDYL-L-ARGINYL-L-CYSTEINYL-L-THREONYL-2-(2-(2-AMINOETHOXY)ETHOXY)ACETYL-L-LYSINAMIDE))-N6.15-CARBONYL)POLYETHYLENE GLYCOL (N = 800-1100); POLY(OXY-1,2-ETHANEDIYL), alpha-HYDRO-omega-HYDROXY-, 15,15'-DIESTER WITH N-ACETYL-L-ISOLEUCYL-L-CYSTEINYL-L-VALYL-1-METHYL-L-TRYPTOPHYL-L-GLUTAMINYL-L-alpha-ASPARTYL-L-TRYPTOPHYLGLYCYL-L-ALANYL-L-HISTIDYL-L-ARGINYL-L-CYSTEINYL-L-THREONYL-2-(2-(2-AMINOETHOXY)ETHOXY)ACETYL-N6-CARBOXY-L-LYSINAMIDE CYCLIC (2->12)-(DISULFIDE); UNII-TO3JYR3BOU; pegcetacoplanum
Pegcetacoplan, also known as APL-2, is a synthetic cyclic peptide conjugated with a polyethylene glycol (PEG) polymer, falling into the category of complement inhibitors. This carbohydrate-based compound is engineered to bind specifically to complement protein C3 and its activation fragment C3b, thereby modulating the activity of the complement cascade. Its unique structure and mechanism allow for targeted inhibition of complement-mediated processes, making it a valuable tool for researchers investigating immune system regulation and complement-associated pathways. The ability of Pegcetacoplan to selectively interact with key complement components has expanded its utility across various experimental and preclinical settings, particularly in the study of diseases and conditions where dysregulation of the complement system plays a pivotal role. Its stability, solubility, and compatibility with a wide range of in vitro and in vivo models further enhance its appeal for scientific applications, facilitating detailed exploration of complement biology and associated cellular responses.
Immunology Research: Within immunology research, Pegcetacoplan serves as a powerful agent for dissecting the role of the complement system in innate and adaptive immune responses. By inhibiting C3 activation, scientists can delineate the contribution of complement to inflammation, phagocytosis, and opsonization processes. Its use enables the development of experimental models that mimic complement dysregulation, providing insights into the pathogenesis of autoimmune and inflammatory diseases. Researchers utilize this compound to investigate the downstream effects of complement inhibition on cytokine production, immune cell recruitment, and tissue homeostasis, advancing our understanding of immune modulation at the molecular level.
Hematological Studies: In hematological research, the application of APL-2 has proven instrumental in elucidating the mechanisms underlying complement-mediated hemolysis and red blood cell destruction. By blocking the formation of C3 convertase and subsequent deposition of C3 fragments on erythrocytes, it allows for the study of complement's impact on blood cell survival and turnover. This is particularly valuable in modeling conditions where excessive complement activation leads to anemia or other hematologic abnormalities. The ability to selectively regulate complement activity with Pegcetacoplan provides researchers with a precise tool for evaluating potential therapeutic strategies aimed at mitigating complement-driven hematological disorders.
Transplantation Science: In the context of transplantation studies, Pegcetacoplan is employed to explore the influence of complement inhibition on graft survival and rejection processes. The compound's capacity to attenuate complement-mediated tissue injury and inflammation supports investigations into the mechanisms of allograft protection and immune tolerance. Researchers leverage its properties to model scenarios of complement activation during organ or tissue transplantation, assessing how modulation of the complement pathway can impact graft outcomes and the development of chronic rejection. These studies contribute to the broader field of transplant immunology by identifying novel approaches to enhance graft longevity and function.
Ophthalmology Research: In ophthalmology research, APL-2 is utilized to examine the role of complement activation in retinal and choroidal diseases. Its targeted inhibition of C3 has facilitated studies into the pathophysiology of complement-driven damage within ocular tissues, enabling the development of experimental systems that recapitulate disease-associated complement dysregulation. By suppressing local complement activity, researchers can evaluate cellular and molecular responses in retinal pigment epithelium, photoreceptors, and choroidal vasculature, deepening our understanding of the interplay between complement and visual function. These investigations pave the way for identifying new molecular targets and pathways involved in ocular disease progression.
Nephrology and Kidney Disease Models: In nephrology research, Pegcetacoplan is employed to investigate the contribution of complement activation to glomerular and tubular injury. Through its inhibition of C3, the compound enables the creation of in vitro and in vivo models that mimic complement-mediated kidney damage, supporting studies into the pathogenesis of proteinuria, glomerulonephritis, and other renal disorders. Researchers utilize it to assess the impact of complement blockade on kidney cell survival, inflammation, and fibrosis, providing valuable information for the development of novel strategies to preserve renal function and prevent disease progression.
Biomarker Discovery and Complement Pathway Analysis: Beyond disease modeling, Pegcetacoplan finds application in the discovery and validation of biomarkers associated with complement activation. Its selective inhibition allows researchers to differentiate between complement-dependent and independent pathways, facilitating the identification of specific molecular signatures linked to complement dysregulation. By incorporating this compound into proteomic and transcriptomic studies, scientists can map changes in cellular signaling networks and gene expression profiles, advancing the field of systems biology and personalized medicine. The versatility and specificity of Pegcetacoplan continue to support a wide spectrum of research endeavors focused on unraveling the complexities of the complement system and its implications for human health and disease.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More